From: Targeting dendritic cells in pancreatic ductal adenocarcinoma
Tumor-associated antigen | Year | Na | Stage | Pulsation | R | SD | PD | Median survival (months) |
---|---|---|---|---|---|---|---|---|
MUC1 | ||||||||
 Pecher et al. [31] | 2002 | 2 | Unresectable | cDNA |  | 0 | 2 |  |
 Kondo et al. [32] | 2008 | 20 | Unresectable | Peptide | 1 | 5 | 14 | 9.8b |
 Lepisto et al. [33] | 2008 | 12 | Resectable | Peptide | 4 |  |  | 26 |
 Rong et al. [34] | 2012 | 7 | Unresectable | Peptide |  | 0 | 7 |  |
 Shindo et al. [35] | 2014 | 42 | Unresectable | mRNA | 4 | 22 | 16 | 13.9 |
WT1 | ||||||||
 Koido et al. [37] | 2014 | 10 | Unresectable | Peptide |  | 7 | 3 |  |
2015 | 7 | Unresectable | Peptide | Â | 6 | 1 | 10.8 | |
 Mayanagi et al. [38] | 2015 | 10 | Unresectable | Peptide |  | 6 | 4 | 8.3 |
 Okamoto et al. [41] | 2016 | 255 | Unresectable | Peptide |  |  |  | 9.9 |
Mesothelin | ||||||||
 Thomas et al. [43] | 2004 | 14 | Unresectable | Peptide | Immunological response in 3 patients | |||
KRAS | ||||||||
 Gjertsen et al. [45] | 1996 | 5 | Unresectable | Peptide |  | 3 | 2 | 5 |
hTERT, CEA, survivin | ||||||||
 Mehrotra et al. [55] | 2017 | 12 | Unresectable | Peptide |  |  |  | 7.7 |
CEA, HER2, WT1 | ||||||||
 Kimura et al. [56] | 2012 | 49 | Unresectable | Peptide | 7 | 10 | 32 | 11.8 |
CEA, MUC1 | ||||||||
 Nakamura et al. [59] | 2009 | 12 | Unresectable | Peptide, lysate |  |  |  | 9 |
Tumor cell lysate | ||||||||
 Bauer et al. [61] | 2011 | 12 | Unresectable | Lysate | 1 | 2 | 9 | 10.5 |